Identity
VK2735 is an investigational dual GIP/GLP-1 receptor agonist.
Selected study only; not a complete clinical review.
Peptide library
VK2735
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The 13-week dose-finding study used a model that excluded observations sufficiently after treatment discontinuation. Its efficacy estimate should not be presented as a treatment-policy effect or long-term maintenance outcome; adverse-event withdrawals matter.
About this assessment
Selected full-text methods/results or correction sections assessed.
This assessment covers selected sources and sections. It is not a systematic review, formal risk-of-bias score, or clinician sign-off.
Editorial assessment · 2026-09-07
Who was studied
Adults with overweight or obesity without diabetes; 13-week phase 2 VENTURE trial.
What the sources found
Mean weight reductions ranged from 9.1% to 14.7% across active groups versus 1.7% with placebo.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
VK2735 is an investigational dual GIP/GLP-1 receptor agonist.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Adverse events were chiefly gastrointestinal; longer follow-up is needed.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Mean weight reductions ranged from 9.1% to 14.7% across active groups versus 1.7% with placebo.
Selected study only; not a complete clinical review.
Adverseeffects
Adverse events were chiefly gastrointestinal; longer follow-up is needed.
Selected study only; not a complete clinical review.
References
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. 2026.
PMID: 41508550
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.